If you are being treated for diabetes with Actos (pioglitazone) you probably are already aware that the Food and Drug Administration has issued a health warning about the medication and is conducting a review of studies showing an increased risk of developing bladder cancer.
In a recent nationwide alert, an FDA official said “An increased risk of bladder cancer was observed among patients with the longest exposure to Actos, as well as in those exposed to the highest cumulative dose of Actos. ”
Now, a newly published report from a massive Chinese diabetes study in Taiwan raises new concerns about a link between Actos and chronic kidney disease.
Chinese doctors studied tests from 35,000 participating patients with diabetes and concluded that those treated with Actos (pioglitazone) were at four times higher risk of developing kidney chronic disease than patients who were not treated with Actos.
The findings of “The Association of Pioglitazone and Urinary Tract Disease in Type 2 Diabetic Taiwanese: Bladder Cancer and Chronic Kidney Disease” were recently published in the scientific journal Plos One.
Although the FDA has alerted the public to the risk of bladder cancer through long-term use of Actos no warning about links to chronic kidney disease — which can result in kidney failure — has been issued.
The bladder cancer concerns are central to a huge number of Actos bladder cancer lawsuits that have been filed across the country and several thousand of which have been consolidated before a federal judge in Louisiana.
Here is a summary of the allegations:
“Each of the actions alleges claims arising from the use of Actos, a prescription medication approved for use in the treatment of type 2 diabetes. Plaintiffs allege that individuals who use Actos face an increased risk of developing bladder cancer. Plaintiffs further allege that the defendants concealed their knowledge of this risk and failed to provide adequate warnings to consumers and the health care community.”
In one of the trials, now being heard in state court in Nevada, a man is seeking over $1 billion in compensation, claiming that Takeda executives knew about the dangerous link to bladder cancer and withheld that information from patients and government regulators.